Sarissa Capital Management LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Sarissa Capital Management LP reported 9 stock positions worth $222.9 million. Its top holding was Innoviva (INVA) at 25.3% of the portfolio, followed by Ironwood Pharmaceuticals (IRWD, 24.1%) and Neurocrine Biosciences (NBIX, 19.3%). Compared with Q3 2025, it opened 1 new position, added to 1 and reduced 1. The biggest buy was a new position in Biohaven (BHVN) and the biggest sale Cytokinetics (CYTK, shares −33%).
- Most Recent 13F
- Q2 2026
- Location
- GREENWICH, CT
- CIK
- 0001577524
- Portfolio Value
- $222.9M (Q4 2025)
- SEC Filing
- 0000899140-26-000256 ↗ filed Feb 17, 2026
Holdings Value
Holdings 9 stocks · $222.9M
| INVA Innoviva Inc. | 25.25% | 2,816,022 | $56.3M | No change |
| IRWD Ironwood Pharmaceuticals Inc. | 24.07% | 15,919,435 | $53.6M | No change |
| NBIX Neurocrine Biosciences Inc. | 19.29% | 303,151 | $43.0M | No change |
| CYTK Cytokinetics Inc. | 11.30% | 396,357 | $25.2M | Reduce -32.6% |
| AMRN Amarin Corp. PLC -ADR | 10.48% | 1,673,395 | $23.4M | Add +34.7% |
| LNTH Lantheus Holdings Inc. | 5.42% | 181,450 | $12.1M | No change |
| BHVN Biohaven Ltd. | 2.60% | 513,184 | $5.8M | New |
| REGN Regeneron Pharmaceuticals | 1.45% | 4,190 | $3.2M | No change |
| VOR Vor Biopharma Inc. | 0.15% | 25,399 | $332K | No change |
Portfolio Sells Q3 2025 → Q4 2025
| CYTK Cytokinetics Inc. | Reduce -32.6% | 11.30% | −6.63 |
Portfolio Buys Q3 2025 → Q4 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $177.9M | INVA, IRWD, AMRN, NBIX, CYTK |
| Q1 2026 | 9 | $157.6M | INVA, IRWD, AMRN, NBIX, CYTK |
| Q4 2025 | 9 | $222.9M | INVA, IRWD, NBIX, CYTK, AMRN |
| Q3 2025 | 8 | $180.4M | INVA, NBIX, CYTK, IRWD, AMRN |
| Q2 2025 | 7 | $154.4M | INVA, NBIX, AMRN, CYTK, IRWD |
| Q1 2025 | 7 | $154.7M | INVA, NBIX, CYTK, IRWD, AMARIN CORP PLC |
| Q4 2024 | 8 | $322.9M | INVA, IRWD, NBIX, CYTK, GILD |
| Q3 2024 | 10 | $402.3M | INVA, IRWD, GILD, CYTK, NBIX |
| Q2 2024 | 10 | $592.4M | BIIB, INVA, IRWD, GILD, CYTK |
| Q1 2024 | 10 | $571.6M | IRWD, BIIB, INVA, GILD, NBIX |